LIFE logo

Lifecare ASA Stock Price

OB:LIFE Community·NOK 89.1m Market Cap
  • 1 Narratives written by author
  • 1 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

LIFE Share Price Performance

NOK 0
-6.50 (-100.00%)
NOK 0.40
Fair Value
NOK 0
-6.50 (-100.00%)
Price NOK 0

LIFE Community Narratives

·
Fair Value NOK 0.4 26.3% undervalued intrinsic discount

TTP Collaboration And Sensor Chemistry Will Streamline Manufacturing

0users have liked this narrative
1users have commented on this narrative
0users have followed this narrative
NOK 0.4
26.3% undervalued intrinsic discount
Profit Margin
21.8%
Future PE
136.27x
Price in 2029
NOK 0.5

Trending Discussion

Updated Narratives

LIFE logo

LIFE: Future Regulatory Clearance And Implant Longevity Results Will Support Repricing Potential

Fair Value: NOK 0.4 26.3% undervalued intrinsic discount
0 users have set this as their fair value
1 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Medium-low risk with mediocre balance sheet.

6 Risks
1 Reward

Lifecare ASA Key Details

NOK 7.4m

Revenue

NOK 0

Cost of Revenue

NOK 7.4m

Gross Profit

NOK 143.5m

Other Expenses

-NOK 136.1m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 19, 2026
-0.46
100.00%
-1,835.15%
0%
View Full Analysis

About LIFE

Founded
2006
Employees
25
CEO
Joacim Holter
WebsiteView website
lifecare.no

Lifecare ASA, together with its subsidiaries, operates as a medical sensor company that develops technology for sensing and monitoring of various body analytes in Norway. The company develops Sencell, a 3D printed nano-sensor for monitoring glucose levels in patients with diabetes and for veterinary applications; as well as medical devices that remove subdermal implants. Lifecare ASA was founded in 2006 and is headquartered in Bergen, Norway.

Recent LIFE News & Updates

Narrative Update May 25

LIFE: Future Regulatory Clearance And Implant Longevity Results Will Support Repricing Potential

The analyst price target for Lifecare has been revised lower to NOK0.40 from NOK0.65, with analysts highlighting a reduced revenue growth outlook, a lower discount rate, a slightly higher profit margin assumption, and a much higher future P/E input in their updated valuation work. Analyst Commentary Analysts are reassessing Lifecare after the latest valuation update, and the revised inputs around growth, margins, discount rate, and future P/E are shaping both the optimistic and cautious views.
Narrative Update May 10

LIFE: Future Regulatory Clearance On CGM Implant Will Support Repricing Potential

Analysts have lifted their price target on Lifecare to NOK 0.65 per share, citing a slightly lower discount rate, a modestly higher forecast profit margin, and a reduced forward P/E assumption that together support a more efficient earnings profile at the same fair value level. Analyst Commentary Recent research commentary on Lifecare centers on how the revised price target aligns with updated assumptions for profitability, discount rates, and forward P/E.

Recent updates

No updates